Partnerships, Patent Wins, and Leadership Changes - Research Report on AbbVie, Edwards Lifesciences, Pharmacyclics, MAKO, and Epizyme

Wed Jul 17, 2013 8:01am EDT

* Reuters is not responsible for the content in this press release.

Partnerships, Patent Wins, and Leadership Changes - Research Report on AbbVie, Edwards Lifesciences, Pharmacyclics, MAKO, and Epizyme

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, July 17, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting AbbVie Inc. (NYSE: ABBV), Edwards Lifesciences Corp. (NYSE: EW), Pharmacyclics Inc. (NASDAQ: PCYC), MAKO Surgical Corp. (NASDAQ: MAKO), and Epizyme Inc. (NASDAQ: EPZM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

AbbVie Inc. Research Report

On July 8, 2013, AbbVie Inc. (AbbVie) reported a new partnership with Stacy London, style expert and co-host of TLC's "What Not to Wear," on a psoriasis campaign called Uncover Your Confidence. According to the Company, the campaign features educational resources and style advice for the estimated 7.5 million American men and women living with psoriasis, a chronic disease of the immune system that appears on the skin which is commonly mistaken as "just a skin condition." Uncover Your Confidence offers Stacy's Guide to Style, with style tips for home and wardrobe for people living with psoriasis, videos of Stacy answering common questions about the conditions and her psoriasis journey, an online search tool to find a dermatologist who manages psoriasis, and an access to the Psoriasis Patient Advocate Program, which pairs those with psoriasis with trained professionals in the area who can provide one-on-one support, education, and resources. The Full Research Report on AbbVie Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/2433_ABBV]

--

Edwards Lifesciences Corp. Research Report

On July 12, 2013, Edwards Lifesciences Corp. (Edwards Lifesciences) announced that the District Court of Mannheim, Germany, has found that Medtronic infringes the Company's Spenser patent for transcatheter heart valve technology. The court granted an injunction prohibiting the sale of CoreValve and CoreValve Evolut systems in Germany, a recall of these products, and an accounting for past damages. Edwards Lifesciences had filed this case in August 2012, which related to three patents, including the Spenser patent EP 2 055 266 B1, which is in effect until October 2022. The Company further informed that the validity of the Spenser patent is being contested separately at the European Patent Office. The Company said that the current decision is appealable, and enforceable when the Company provides the required bond to support the injunction. The Full Research Report on Edwards Lifesciences Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/4fbc_EW]

--

Pharmacyclics Inc. Research Report

On July 10, 2013, Pharmacyclics Inc. (Pharmacyclics) announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, for two relapsed/refractory B-cell malignancy indications: mantel cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). The Company said that its submission was based on data from Phase II studies in patients with relapsed/refractory MCL and in patients with relapsed/refractory CLL/SLL. The Company is also requesting Priority Review. Bob Duggan, Chairman and Chief Executive Officer of Pharmacyclics, said, "Thus far, more than 1600 patients have been treated in our studies with ibrutinib and we are making excellent progress in the development and preparation for commercialization of this investigational drug. As of today, we have initiated 7 Phase III studies together with our partner Janssen and have currently registered with the US National Institute of Health 31 clinical trials using ibrutinib." The Full Research Report on Pharmacyclics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/dd7a_PCYC]

--

MAKO Surgical Corp. Research Report

On July 8, 2013, MAKO Surgical Corp. (MAKO) announced that Scott D. Flora and Jonathan T. "Jack" Lord, M.D., have joined the Company's Board of Directors. Mr. Flora is currently the President, Chief Executive Officer, and Director of OmniGuide Inc., a medical device Company. He also served as the Global Business Unit President for the surgical device division of Covidien plc, from November 2006 until June 2011. Further, MAKO informed that Dr. Lord is currently the Chairman of the Board of Directors of Dexcom, Inc., which is also a medical device company. He previously served as the Chief Operating Officer of the Miller School of Medicine and UHealth-University of Miami Health System, and is currently a Professor of Clinical Pathology.The Full Research Report on MAKO Surgical Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/7865_MAKO]

--

Epizyme Inc. Research Report

On July 3, 2013, Epizyme, Inc. (Epizyme) announced that Jason P. Rhodes, Executive Vice President and Chief Financial Officer, has been named the President of Epizyme. The Company informed that Mr. Rhodes will continue to serve as the Chief Financial Officer of the Company. Robert J. Gould, Ph.D., Chief Executive Officer, said, "Jason joined Epizyme in March 2010 and has been instrumental in our growth and success." "He has served as Chief Business Officer and Chief Financial Officer during his tenure and has been a key partner for me in building the business and charting our strategic course." Prior to joining Epizyme, Mr. Rhodes served as Vice President, Business Development at Alnylam Pharmaceuticals, Inc. (Alnylam). According to the Company, Mr. Rhodes drove the establishment and the management of several key strategic alliances and contributed to the growth of the business in Alnylam. The Full Research Report on Epizyme Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/0f2f_EPZM]

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


SOURCE Wall Street Reports

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.